Divergent kinetics differentiate the mechanism of action of two HDAC inhibitors

Biochemistry

Volumn 53, Issue 4, 2014, Pages 725-734

  Kral, Astrid M ^a,b   Ozerova, Nicole ^a,c   Close, Joshua ^a   Jung, Joon ^a,d   Chenard, Melissa ^a   Fleming, Judith ^a,e   Haines, Brian B ^a   Harrington, Paul ^a,f   Maclean, John ^a   Miller, Thomas A ^a   Secrist, Paul ^a,b   Wang, Hongmei ^a   Heidebrecht, Richard W ^a,g  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ASTRAZENECA   (United Kingdom)

^c Reynolds and Reynolds   (United States)

^d Ironwood Pharmaceuticals   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f AMGEN INC   (United States)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONFORMATIONAL CHANGE; ENZYMATIC ASSAY; HDAC INHIBITORS; HISTONE DEACETYLASES; MECHANISM OF ACTION; MICHAELIS-MENTEN KINETIC; OPTIMAL BINDING; SELECTIVE INHIBITORS;

ASSAYS;

DISEASES;

HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CONFORMATIONAL TRANSITION; DRUG BINDING; DRUG MECHANISM; DRUG STRUCTURE; ENZYMATIC ASSAY; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOATES; CELL LINE, TUMOR; FEMALE; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT DYES; HETEROGRAFTS; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; KINETICS; MICE; MICE, NUDE; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; SUBSTRATE SPECIFICITY; XANTHENES;

EID: 84893699626     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi400936h     Document Type: Article

References (26)

1. Reviewed in Witt, O., Deubzer, H. E., Milde, T., and Oehme, I. (2009) HDAC Family: What are the Cancer Relevant Targets? Cancer Lett. 277, p8-21
2. Suzuki, T., Yokozaki, H., Kuniyasu, H., Hayashi, K., Naka, K., Ono, S., and Ishikawa, T. (2000) Effect of Trichostatin A on Cell Growth and Expression of Cell Cycle- and Apoptosis-Related Molecules in Human Gastric and Oral Carcinoma Cell Lines Int. J. Cancer 88, 992-997
3. Curtin, M. and Glaser, K. (2003) Histone Deacetylase Inhibitors: The Abbott Experience Curr. Med. Chem. 22, 2373-2392 (Pubitemid 37236394)
4. Choi, J. H., Kwon, H. J., Yoon, B. I., Kim, J. H., Han, S. U., Joo, H. J., and Kim, D. Y. (2001) Expression Profile of Histone Deacetylase 1 in Gastric Cancer Tissues Jpn. J. Cancer Res. 92, 1300-1304 (Pubitemid 34036893)
5. Zhu, P., Martin, E., Mengwasser, J., Schlag, P., Janssen, K. P., and Göttlicher, M. (2004) Induction of HDAC2 Expression upon Loss of APC in Colorectal Tumorigenesis Cancer Cell. 5, 455-463 (Pubitemid 38610247)
6. Krishnan, M., Singh, A. B., Smith, J. J., Sharma, A., Chen, X., Eschrich, S., Yeatman, T. J., Beauchamp, R. D., and Dhawan, P. (2010) HDAC Inhibitors Regulate Claudin-1 Expression in Colon Cancer Cells through Modulation of mRNA Stability Oncogene 29, 305-312
7. Zimmermann, S., Kiefer, F., Prudenziati, M., Spiller, C., Hansen, J., Floss, T., Wurst, W., Minucci, S., and Göttlicher, M. (2007) Reduced Body Size and Decreased Intestinal Tumor Rates in HDAC2-Mutant Mice Cancer Res. 67, 9047-54 (Pubitemid 47535889)
8. Bicaku, E., Marchion, D. C., Schmitt, M. L., and Münster, P. N. (2008) Selective Inhibition of Histone Deacetylase 2 Silences Progesterone Receptor-Mediated Signaling Cancer Res. 68, 1513-1519 (Pubitemid 351346860)
9. Reviewed in Karagiannis, T. C. and El-Osta, A. (2007) Will Broad-Spectrum Histone Deacetylase Inhibitors Be Superseded by More Specific Compounds? Leukemia 21, 61-65 (Pubitemid 44921835)
10. Hamblett, C. L., Methot, J. L., Mampreian, D. M., Sloman, D. L., Stanton, M. G., Kral, A. M., Fleming, J. C., Cruz, J. C., Chenard, M., Ozerova, N., Hitz, A. M., Wang, H., Deshmukh, S. V., Nazef, N., Harsch, A., Hughes, B., Dahlberg, W. K., Szewczak, A. A., Middleton, R. E., Mosley, R. T., Secrist, J. P., and Miller, T. A. (2007) The Discovery of 6-Amino Nicotinamides As Potent and Selective Histone Deacetylase Inhibitors Bioorg. Med. Chem. Lett. 17, 5300-5309 (Pubitemid 47391291)
11. Swillens, S. (1995) Interpretation of Binding Curves Obtained with High Receptor Concentrations: Practical Aid for Computer Analysis Mol. Pharmacol. 47, 1197-1203
12. Munson, P. J. and Rodbard, D. (1988) An Exact Correction to the "Cheng-Prusoff" Correction J. Recept. Res. 8, 533-546
13. Case, D. A., Darden, T. A., Cheatham, T. E., III, Simmerling, C. L., Wang, J., Duke, R. E., Luo, R., Merz, K. M., Wang, B., Pearlman, D. A., Crowley, M., Brozell, S., Tsui, V., Gohlke, H., Mongan, J., Hornak, V., Cui, G., Beroza, P., Schafmeister, C., Caldwell, J. W., Ross, W. S., and Kollman, P. A. (2004), AMBER 8, University of California, San Francisco.
14. Friesner, R. A., Murphy, R. B., Repasky, M. P., Frye, L. L., Greenwood, J. R., Halgren, T. A., Sanschagrin, P. C., and Mainz, D. T. (2006) Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein-Ligand Complexes J. Med. Chem. 49, 6177-6196 (Pubitemid 44595196)
15. Shivakumar, D., Williams, J., Wu, Y., Damm, W., Shelley, J., and Sherman, W. (2010) Prediction of Absolute Solvation Free Energies Using Molecular Dynamics Free Energy Perturbation and the OPLS Force Field J. Chem. Theor. Comput. 6, 1509-1519
16. Witter, D. J., Harrington, P., Wilson, K., Chenard, M., Fleming, J. C., Haines, B., Kral, A. M., Secrist, J. P., and Miller, T. A. (2008) Optimization of Biaryl Selective HDAC1&2 Inhibitors (SHI-1: 2) Bioorg. Med. Chem. Lett. 18, 726-731
17. Bressi, J. C., Jennings, A. J., Skene, R., Wu, Y., Melkus, R., De Jong, R., O'Connell, S., Grimshaw, C. E., Navre, M., and Gangloff, A. R. (2010) Exploration of the HDAC2 Foot Pocket: Synthesis and SAR of Substituted N-(2-Aminophenyl)benzamides Bioorg. Med. Chem. Lett. 20, 3142-3145
18. Copeland, R. A. (2005) Evaluation of Enzyme Inhibitors In Drug Discovery, pp 113-132, 141-155, Wiley-Interscience, NJ.
19. Cheng, Y.-C. and Prusoff, W. H. (1973) Relationship between the Inhibition Constant (K1) and the Concentration of Inhibitor Which Causes 50% Inhibition (I50) of an Enzymatic Reaction Biochem. Pharmacol. 22, 3099-3108
20. USPTO Application 20090156825, 2009.
21. Chou, C. J., Herman, D., and Gottesfeld, J. M. (2008) Pimelic Diphenylamide 106 Is a Slow, Tight-Binding Inhibitor of Class I Histone Deacetylases J. Biol. Chem. 51, 35402-35409
22. Schultz, B. E., Misialek, S., Wu, J., Tang, J., Conn, M. T., Tahilramani, R., and Wong, L. (2004) Kinetics and Comparative Reactivity of Human Class I and Class IIb Histone Deacetylases Biochemistry 43, 11083-11091 (Pubitemid 39433697)
23. Beckers, T., Burkhardt, C., Wieland, H., Gimmnich, P., Ciossek, T., Maier, T., and Sanders, K. (2007) Distinct Pharmacological Properties of Second Generation HDAC Inhibitors with the Benzamide or Hydroxamate Head Group Int. J. Cancer 121, 1138-1148 (Pubitemid 47101654)
24. Methot, J. L., Chakravarty, P. K., Chenard, M., Close, J., Cruz, J. C., Dahlberg, W. K., Fleming, J., Hamblett, C. L., Hamill, J. E., Harrington, P., Harsch, A., Heidebrecht, R., Hughes, B., Jung, J., Kenific, C. M., Kral, A. M., Meinke, P. T., Middleton, R. E., Ozerova, N., Sloman, D. L., Stanton, M. G., Szewczak, A. A., Tyagarajan, S., Witter, D. J., Secrist, J. P., and Miller, T. A. (2008) Exploration of the Internal Cavity of Histone Deacetylase (HDAC) with Selective HDAC1/HDAC2 Inhibitors (SHI-1:2) Bioorg. Med. Chem. Lett. 18, 973-978 (Pubitemid 351179353)
25. Butler, L. M., Agus, D. B., Scher, H. I., Higgins, B., Rose, A., Cordon-Cardo, C., Thaler, H. T., Rifkind, R. A., Marks, P. A., and Richon, V. M. (2000) Suberoylanilide Hydroxamic Acid, an Inhibitor of Histone Deacetylase, Suppresses the Growth of Prostate Cancer Cells in Vitro and in Vivo Cancer Res. 60, 5165-5170
26. Bressan, A., Bigioni, M., Bellarosa, D., Nardelli, F., Irrisuto, C., Maggi, C. A., and Binaschi, M. (2010) Induction of a Less Aggressive Phenotype in Human Colon Carcinoma HCT116 Cells by Chronic Exposure to HDAC Inhibitor SAHA Oncol. Rep. 24, 1249-1255